Better Labels for a Popular YAZ Contraceptive
The popular contraceptive Yasmin first hit the market in 2001 after the U.S. Food and Drug Administration (FDA) approved the prescription birth control pill in 2001 and its sister pill Yaz in 2006. Both are manufactured and marketed by the pharmaceutical giant Bayer Healthcare Pharmaceuticals and both contain a synthetic hormone called drospirenone (progestin).
Since the contraceptives have been on the market, there have been reports of adverse effects from ingesting the drugs such as deep vein thrombosis and stroke. This triggered a lengthy FDA investigation which conclusively found that women who have taken the fourth generation pills containing drospirenone had a significantly higher risk of developing a blood clot. As a result of these studies, the FDA announced that pills containing drospirenone would be required to label their drugs with detailed information concerning the increased risk of developing a blood clot.
Following the FDA’s labeling demand in 2011, Bayer announced its intention to pay out $110 million dollars in Yaz settlements on April 10, 2012, for claims involving blood clots. Thousands of lawsuits were initiated over the years claiming blood clot-related injuries from plaintiff’s alleging that Bayer did not adequately warn of the risks associated with taking Yasmin and Yaz. The Bayer settlement could mark the first of many more settlements to come for injured plaintiffs.
If you have taken Yaz or Yasmin, there are warning signs of developing a blood clot. Some include severe headaches, swelling or pain in the arms or legs, sharp chest pain, pain or tenderness in one leg, a temperature difference in the legs, shortness of breath, rapid heart rate, sudden cough, and blurred vision. Pulmonary embolism (blood clots in the lung), deep vein thrombosis (blood clots in the legs), heart attack and stroke are all conditions caused by blood clots.
If you have taken Yasmin or Yaz and have experienced any of the above-named symptoms, please contact Khorrami, LLP for a consultation.